These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
982 related articles for article (PubMed ID: 12527708)
1. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849 [TBL] [Abstract][Full Text] [Related]
3. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma]. Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653 [TBL] [Abstract][Full Text] [Related]
4. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Kiss A; Wang NJ; Xie JP; Thorgeirsson SS Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784 [TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035 [TBL] [Abstract][Full Text] [Related]
6. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336 [TBL] [Abstract][Full Text] [Related]
7. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. D'Errico A; Fiorentino M; Ponzetto A; Daikuhara Y; Tsubouchi H; Brechot C; Scoazec JY; Grigioni WF Hepatology; 1996 Jul; 24(1):60-4. PubMed ID: 8707284 [TBL] [Abstract][Full Text] [Related]
8. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020 [TBL] [Abstract][Full Text] [Related]
9. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118 [TBL] [Abstract][Full Text] [Related]
10. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945 [TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Bedossa P; Peltier E; Terris B; Franco D; Poynard T Hepatology; 1995 Mar; 21(3):760-6. PubMed ID: 7875675 [TBL] [Abstract][Full Text] [Related]
12. Expression of hepatocyte growth factor and c-MET in skull base chordoma. Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912 [TBL] [Abstract][Full Text] [Related]
13. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E Hepatology; 1997 Mar; 25(3):619-23. PubMed ID: 9049208 [TBL] [Abstract][Full Text] [Related]
14. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Neaud V; Faouzi S; Guirouilh J; Le Bail B; Balabaud C; Bioulac-Sage P; Rosenbaum J Hepatology; 1997 Dec; 26(6):1458-66. PubMed ID: 9397985 [TBL] [Abstract][Full Text] [Related]
15. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. Varnholt H; Asayama Y; Aishima S; Taguchi K; Sugimachi K; Tsuneyoshi M Oncol Rep; 2002; 9(1):35-41. PubMed ID: 11748452 [TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771 [TBL] [Abstract][Full Text] [Related]
17. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Buckley AF; Burgart LJ; Kakar S Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Osada S; Kanematsu M; Imai H; Goshima S Hepatogastroenterology; 2008; 55(82-83):544-9. PubMed ID: 18613405 [TBL] [Abstract][Full Text] [Related]
20. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Nagata K; Hirono S; Ido A; Kataoka H; Moriuchi A; Shimomura T; Hori T; Hayashi K; Koono M; Kitamura N; Tsubouchi H Biochem Biophys Res Commun; 2001 Nov; 289(1):205-11. PubMed ID: 11708800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]